ArticleScientific reports2025
Multi-step organic synthesis, cytotoxicity, and molecular docking of new N-phenylpyrazolones incorporated with N-benzylthiazole or N-benzyl-4-thiazolone fragments.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Building on our previous research on edaravone-derived bioactive small molecules, the precursors 2-5 were synthesized by condensation reactions between 4-{[(4-acetylphenyl)amino]methylidene}-5-methyl-2-phenylpyrazol-3-one (1) and a variety of organic hydrazines. Next, diversity-oriented S, N-heterocyclization of 2 was employed to access N-phenylpyrazolone-N-benzylthiazole hybrids bearing an azo phenyl fragment (6a,b) and N-phenylpyrazolone-N-benzyl-4-thiazolone hybrids linked to an acrylate unit (7a,b). S, N-heterocyclization to access 6a,b was started by Williamson thioether synthesis between 2 and arene hydrazonoyl halides, while in 7a,b it was commenced via 1,4-thia-Michael addition between 2 and activated alkynes. The molecular structures of these uncommon hybrids were confirmed by instrumental analyses. Their cytotoxicity activity against osteosarcoma (Hos), non-small lung (A549), and colon carcinoma (HCT-116) cancer cell lines was tested via MTT bioassay using doxorubicin as a medical reference. The precursor 4 that bears a sulfonamide fragment is the sole molecule that is cytotoxic against all the tested cell lines, with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.